Published on

Oncology-Alkylating Agents

I. Introduction

Alkylating agents are antiproliferative cytotoxic drugs used in cancer chemotherapy. They function by covalently binding to DNA via alkyl groups, primarily causing cross-linking. This leads to cell cycle arrest (G1-S transition), followed by either DNA repair or apoptosis (programmed cell death).

II. Clinical Use

Alkylating agents are widely used to treat:

  • Leukemia
  • Lymphoma
  • A range of solid tumors

III. Mechanisms of Resistance

Resistance to alkylating agents is complex and varies depending on the specific agent. Key mechanisms include:

  • Enhanced DNA repair: Increased expression of enzymes like O6-alkyltransferase (especially relevant for nitrosoureas).
  • Increased detoxification: Elevated levels of:
    • Glutathione
    • Metallothionein
    • Glutathione-S-transferase

IV. Examples of Alkylating Agents

This section details key characteristics, uses, and toxicities of specific alkylating agents. Pay close attention to the differences in their mechanisms, side effects, and clinical applications.

Agent

Description

Clinical Use

Key Toxicities

Notes

Melphalan

Nitrogen mustard derivative + phenylalanine (targets dividing cells via amino acid uptake)

Leukemia, lymphoma, solid tumors

Myelosuppression (bone marrow suppression)

Chlorambucil

Phenylbutyric acid derivative of nitrogen mustard (oral administration)

Solid and hematological malignancies

Myelosuppression

Well-absorbed orally

Cyclophosphamide

Extensively used; pro-drug activated by hepatic P450

Broad range of cancers

Marrow suppression, alopecia, nausea, vomiting

Relatively low non-hematological toxicity; used in high-dose regimens

Ifosfamide

Isomer of cyclophosphamide; metabolized to chloroacetaldehyde (toxic metabolite)

Broad range of cancers

Alopecia, hemorrhagic cystitis (mitigated by mesna)

Mesna co-administration is crucial to reduce hemorrhagic cystitis

Busulfan

Specific use in Chronic Myelogenous Leukemia (CML)

CML

Myelosuppression, hepatic veno-occlusive disease, hyperpigmentation, pulmonary fibrosis

Well absorbed from GI tract

Carmustine (BCNU)

Lipophilic molecule

CNS tumors, high-dose conditioning

Myelosuppression

Temozolomide

Newer agent

Glioma, melanoma

Important Note: Both cyclophosphamide and ifosfamide are pro-drugs activated by hepatic cytochrome P450 to form nitrogen mustards. Remember the differences in their toxicity profiles and how those toxicities are managed clinically.

0 Comments

Kembara Xtra 

Facts about medicine and its subtopic such as anatomy, physiology, biochemistry, pharmacology, medicine, pediatrics, psychiatry, obstetrics and gynecology and surgery.